X0306 4 2020-02-07 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001557146 Lloyd-Smith Malcolm 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Regulatory Officer Common Stock 2020-02-07 4 S 0 1015 103.2774 D 23200 D Common Stock 2020-02-10 4 M 0 13042 32.99 A 36242 D Common Stock 2020-02-10 4 S 0 13042 104.563 D 23200 D Common Stock 2020-02-10 4 M 0 15927 81.49 A 39127 D Common Stock 2020-02-10 4 S 0 15927 104.563 D 23200 D Incentive Stock Option 32.99 2020-02-10 4 M 0 13042 0.00 D 2025-02-03 Common Stock 13042 0 D Non-Qualified Stock Option 81.49 2020-02-10 4 M 0 15927 0.00 D 2028-02-05 Common Stock 15927 17596 D Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.56 to $105.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted February 3, 2015 and vested monthly over four years. Option granted February 5, 2018 and vests monthly over four years. /s/ Darin Lippoldt, Attorney-in-Fact 2020-02-11